Finance

Lists
BVS:NASDAQ
Bioventus Inc
14,02 USD
+1,52%
(+0,21) 1D
14,02 USD
0,00% (0,00)
After hours
Closed: 28-сен., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BVS...
Open
13,81 USD
High
14,10 USD
Low
13,64 USD
Mkt. cap
1,16 млд
Avg. vol.
524,90 миң
Volume
112,00
52-wk high
15,89 USD
52-wk low
6,37 USD
Beta
0,65
Shares outstanding
68,30 млн
No. of employees
950
Open
13,81 USD
High
14,10 USD
Low
13,64 USD
Mkt. cap
1,16 млд
Avg. vol.
524,90 миң
Volume
112,00
52-wk high
15,89 USD
52-wk low
6,37 USD
Beta
0,65
Shares outstanding
68,30 млн
No. of employees
950
News stories
From web sources and news partners
About Bioventus Inc
CEO-
Employees950
Founded2011
Headquarters-
SectorMedical device
Websitebioventus.com
Analyst ratings
Based on 4 analysts giving stock ratings to BVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for BVS in the last 3 months.
Highest
Current 14,02 USD
19,00 USD (+35,52%)
Average
17,50 USD (+24,82%)
Lowest
15,00 USD (+6,99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Cantor Fitzgerald
Buy
Reiterated
15,00 USD
+7%
08/17/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
19,00 USD
+35,5%
08/17/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
19,00 USD
+35,5%
08/17/2026
Chase Knickerbocker
Craig-Hallum
Buy
Reiterated
18,00 USD
+28,4%
08/06/2026
Michael Petusky
Barrington
Buy
Maintained
18,00 USD
+28,4%
08/06/2026
Lawrence Solow
CJS Securities
Buy
Initiated
14,00 USD
-0,1%
03/27/2026
Last report
2026-ж., 5-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
0,22 USD / 0,22 USD
+0,92%beat
Revenue / Est. (USD)
153,21 млн / 155,64 млн
-1,56%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
138,65 млн
157,90 млн
132,09 млн
153,21 млн
Cost of goods sold
44,42 млн
49,12 млн
41,32 млн
47,54 млн
Cost of revenue
44,42 млн
49,12 млн
41,32 млн
47,54 млн
Research and development expenses
2,92 млн
3,01 млн
2,47 млн
3,17 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
78,64 млн
82,76 млн
78,31 млн
82,72 млн
Operating expense
82,96 млн
87,06 млн
81,88 млн
86,93 млн
Total operating expenses
127,39 млн
136,18 млн
123,20 млн
134,47 млн
Operating income
11,26 млн
21,72 млн
8,89 млн
18,73 млн
Other non operating income
-79,00 миң
-2,01 млн
427,00 миң
-
EBT including unusual items
4,67 млн
14,14 млн
4,52 млн
15,31 млн
EBT excluding unusual items
5,01 млн
16,38 млн
4,99 млн
14,92 млн
Income tax expense
664,00 миң
-3,18 млн
571,00 миң
-20,90 млн
Effective tax rate
14,22%
-22,45%
12,64%
-136,51%
Other operating expenses
-
-
-
-
Net income
3,16 млн
14,76 млн
3,11 млн
33,44 млн
Net profit margin
2,28%
9,34%
2,36%
21,83%
Earnings per share
0,15
0,24
0,15
0,22
Interest and investment income
-
-
-
-
Interest expense
-6,18 млн
-5,31 млн
-4,33 млн
-4,07 млн
Net interest expenses
-6,18 млн
-5,31 млн
-4,33 млн
-4,07 млн
Depreciation and amortization charges
1,40 млн
1,30 млн
1,11 млн
1,04 млн
EBITDA
22,67 млн
27,05 млн
20,09 млн
29,68 млн
Gain or loss from assets sale
-1,00 миң
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору